We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agios (AGIO) Q4 Earnings & Revenues Fall Short of Estimates
Read MoreHide Full Article
Agios Pharmaceuticals, Inc. (AGIO - Free Report) reported a loss of $1.72 per share in fourth-quarter 2023, wider than the Zacks Consensus Estimate of a loss of $1.64. In the year-ago quarter, the company posted a loss of 67 cents per share.
AGIO reported revenues of $7.1 million, which also missed the Zacks Consensus Estimate of $8 million. In the year-ago quarter, the company recorded revenues of $4.3 million.
Quarter in Detail
In the reported quarter, revenues were generated entirely from product revenues of Agios’ only marketed drug, Pyrukynd (mitapivat), which is approved for treating hemolytic anemia in adults with pyruvate kinase (PK) deficiency.
Pyrukynd revenues in the United States were up 65.1% year over year but declined 4% sequentially. The reported figure missed our model estimate of $7.7 million.
The sequential decline in Pyrukynd revenues was due to lower customer inventory levels at the end of the fourth quarter of 2023.
Given the ultra-rare nature of the disease and long lead times associated with initiating patients on therapy, management expects slow and steady growth, with quarter-to-quarter variability in 2024.
Research & development expenses totaled $77.5 million, up 10.2% year over year. The increase was due to higher development costs for mitapivat and the upfront payment related to the license agreement with Alnylam Pharmaceuticals (ALNY - Free Report) .
Selling, general and administrative expenses increased 7.6% year over year to $35.3 million.
As of Dec 31, 2023, cash, cash equivalents and marketable securities totaled $806.4 million compared with $872.4 million as of Sep 30, 2023. Management expects this cash balance to fund its operations and meet capital expenditure requirements at least into 2026.
Shares of Agios have lost 3.1% in the past year against the industry’s growth of 3.8%.
Image Source: Zacks Investment Research
Full-Year Results
For 2023, AGIO generated revenues of $26.8 million, up 88.4% year over year.
For the same period, the company reported a loss of $6.33 per share compared with a loss of $4.23 in 2022.
Pipeline Updates
AGIO is evaluating mitapivat in the phase III studies — ENERGIZE and ENERGIZE-T — for the treatment of adults with thalassemia.
In January 2024, the company announced that the phase III ENERGIZE study, evaluating orally-administered mitapivat in non-transfusion-dependent thalassemia patients, achieved its primary and key secondary endpoints.
Data from the ENERGIZE study showed that patients treated with mitapivat demonstrated a statistically significant increase in hemoglobin response, the primary endpoint of the study.
Top-line data from the phase III ENERGIZE-T study, which is evaluating mitapivat in adults with transfusion-dependent alpha or beta-thalassemia, is expected by mid-2024.
Agios plans to submit regulatory filings to the FDA seeking approval for mitapivat by 2024-end.
Meanwhile, the company plans to complete enrollment in the phase III portion of the RISE UP study investigating mitapivat in sickle cell disease by the end of 2024.
Agios is evaluating its PKR activator candidate, AG-946, for lower-risk myelodysplastic syndrome (LR-MDS). Patient dosing in the phase IIb study on AG-946 is expected to begin in mid-2024.
The company has also filed an investigational new drug application with the FDA to begin clinical development of its phenylalanine hydroxylase stabilizer, AG-181, for treating phenylketonuria.
In August, Agios and Alnylam announced an exclusive worldwide license agreement. The agreement grants Agios the right to develop and market Alnylam’s preclinical siRNA, targeting TMPRSS6 as a potential disease-modifying therapy for patients with polycythemia vera, a rare and potentially fatal hematologic disease. Other than the upfront payment, Alnylam is eligible to receive potential milestone payments of up to $130 million and tiered royalties.
In the past 60 days, estimates for Exact Sciences’ 2024 loss per share have narrowed from $1.22 to $1.15. In the past year, shares of EXAS have lost 3.8%.
Exact Sciences’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 44.21%.
In the past 60 days, estimates for Puma Biotechnology’s 2024 earnings per share have improved from 64 cents to 69 cents. In the past year, shares of PBYI have risen 60.1%.
Earnings of Puma Biotechnology beat estimates in three of the last four quarters while missing the same on the remaining occasion. PBYI delivered a four-quarter average earnings surprise of 76.55%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Agios (AGIO) Q4 Earnings & Revenues Fall Short of Estimates
Agios Pharmaceuticals, Inc. (AGIO - Free Report) reported a loss of $1.72 per share in fourth-quarter 2023, wider than the Zacks Consensus Estimate of a loss of $1.64. In the year-ago quarter, the company posted a loss of 67 cents per share.
AGIO reported revenues of $7.1 million, which also missed the Zacks Consensus Estimate of $8 million. In the year-ago quarter, the company recorded revenues of $4.3 million.
Quarter in Detail
In the reported quarter, revenues were generated entirely from product revenues of Agios’ only marketed drug, Pyrukynd (mitapivat), which is approved for treating hemolytic anemia in adults with pyruvate kinase (PK) deficiency.
Pyrukynd revenues in the United States were up 65.1% year over year but declined 4% sequentially. The reported figure missed our model estimate of $7.7 million.
The sequential decline in Pyrukynd revenues was due to lower customer inventory levels at the end of the fourth quarter of 2023.
Given the ultra-rare nature of the disease and long lead times associated with initiating patients on therapy, management expects slow and steady growth, with quarter-to-quarter variability in 2024.
Research & development expenses totaled $77.5 million, up 10.2% year over year. The increase was due to higher development costs for mitapivat and the upfront payment related to the license agreement with Alnylam Pharmaceuticals (ALNY - Free Report) .
Selling, general and administrative expenses increased 7.6% year over year to $35.3 million.
As of Dec 31, 2023, cash, cash equivalents and marketable securities totaled $806.4 million compared with $872.4 million as of Sep 30, 2023. Management expects this cash balance to fund its operations and meet capital expenditure requirements at least into 2026.
Shares of Agios have lost 3.1% in the past year against the industry’s growth of 3.8%.
Full-Year Results
For 2023, AGIO generated revenues of $26.8 million, up 88.4% year over year.
For the same period, the company reported a loss of $6.33 per share compared with a loss of $4.23 in 2022.
Pipeline Updates
AGIO is evaluating mitapivat in the phase III studies — ENERGIZE and ENERGIZE-T — for the treatment of adults with thalassemia.
In January 2024, the company announced that the phase III ENERGIZE study, evaluating orally-administered mitapivat in non-transfusion-dependent thalassemia patients, achieved its primary and key secondary endpoints.
Data from the ENERGIZE study showed that patients treated with mitapivat demonstrated a statistically significant increase in hemoglobin response, the primary endpoint of the study.
Top-line data from the phase III ENERGIZE-T study, which is evaluating mitapivat in adults with transfusion-dependent alpha or beta-thalassemia, is expected by mid-2024.
Agios plans to submit regulatory filings to the FDA seeking approval for mitapivat by 2024-end.
Meanwhile, the company plans to complete enrollment in the phase III portion of the RISE UP study investigating mitapivat in sickle cell disease by the end of 2024.
Agios is evaluating its PKR activator candidate, AG-946, for lower-risk myelodysplastic syndrome (LR-MDS). Patient dosing in the phase IIb study on AG-946 is expected to begin in mid-2024.
The company has also filed an investigational new drug application with the FDA to begin clinical development of its phenylalanine hydroxylase stabilizer, AG-181, for treating phenylketonuria.
In August, Agios and Alnylam announced an exclusive worldwide license agreement. The agreement grants Agios the right to develop and market Alnylam’s preclinical siRNA, targeting TMPRSS6 as a potential disease-modifying therapy for patients with polycythemia vera, a rare and potentially fatal hematologic disease. Other than the upfront payment, Alnylam is eligible to receive potential milestone payments of up to $130 million and tiered royalties.
Zacks Rank & Stocks to Consider
Agios currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the healthcare sector are Exact Sciences Corp. (EXAS - Free Report) and Puma Biotechnology, Inc. (PBYI - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Exact Sciences’ 2024 loss per share have narrowed from $1.22 to $1.15. In the past year, shares of EXAS have lost 3.8%.
Exact Sciences’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 44.21%.
In the past 60 days, estimates for Puma Biotechnology’s 2024 earnings per share have improved from 64 cents to 69 cents. In the past year, shares of PBYI have risen 60.1%.
Earnings of Puma Biotechnology beat estimates in three of the last four quarters while missing the same on the remaining occasion. PBYI delivered a four-quarter average earnings surprise of 76.55%.